New flashes, a sudden shower of floaters or a curtain in the visual field need urgent retinal assessment. Establish whether there is a tear or a detachment, document foveal involvement and plan treatment with a vitreoretinal specialist. Good central acuity and a negative ultrasound do not exclude every sight-threatening peripheral lesion.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Recognise the detachment and protect the fovea
In rhegmatogenous retinal detachment (RRD; Amotio), liquefied vitreous passes through a full-thickness retinal break into the subretinal space. A tear, traction and the distribution of subretinal fluid must be considered together rather than treating every peripheral lesion as the same problem. 1 2
New photopsias, suddenly increased floaters, a shadow or a curtain require prompt examination, especially after trauma or ocular surgery. A retina that is still attached centrally can retain good acuity despite extensive peripheral detachment; neither that acuity nor a quiet-looking anterior segment is reassuring on its own. 1
Document the location and number of breaks, detachment extent, foveal and macular status, lens status and proliferative vitreoretinopathy (PVR). Record the onset of symptoms and central visual loss separately from the time of presentation; they are different clocks when interpreting timing studies. 1 2 7
Surgery aims to reattach the retina and preserve or restore useful vision. Anatomical repair does not guarantee normal visual function. The German DOG/BVA2011 surgical guideline is historical; the AWMF045-033 entry from June 2026 is a guideline registration, not a completed new treatment guideline. 2 3
02Examine the vitreous and the whole peripheral retina
Posterior vitreous detachment (PVD) separates the posterior vitreous cortex from the retinal internal limiting membrane. Separation can be partial or complete. Persistent focal adhesion, particularly near the vitreous base or lattice margins, can transmit traction and produce a horseshoe tear. 1
The vitreous base is an area of strong adhesion. Record the PVD status and residual traction; this informs the tear search and, if surgery is needed, the operative strategy. Inducing a PVD and shaving the base are technical decisions, not a guarantee that every eye can be made free of traction without risk. 1
Take a history of flashes, floaters and field loss, trauma, myopia, family or fellow-eye detachment and previous procedures. Measure acuity, assess the visual field and relative afferent pupillary defect (RAPD), and look for vitreous pigment or haemorrhage. Symptoms alone cannot reliably distinguish PVD with a tear from PVD without one. 1
The preferred dynamic examination of peripheral vitreoretinal pathology is dilated indirect ophthalmoscopy with scleral depression. Appropriate contact or condensing-lens slit-lamp examination can also be used in a fully dilated eye, and difficult cases may need both. The clinical goal is an adequate view of the entire relevant periphery, not an unsupported examination-board fail rule. 1
If opacity or cooperation prevents an adequate view, use B-scan ultrasonography to assess for detachment, tears or other causes of opacity. Wide-field photographs can help but do not replace careful ophthalmoscopy. Reported ultrasound sensitivity for tears in fundus-obscuring PVD-associated haemorrhage varies widely; a negative scan is not a universal exclusion test. 1
Haemorrhagic PVD has a higher tear risk and may conceal several breaks. With a fully obscured fundus, the AAO guideline describes close, often weekly review until haemorrhage clears or a thorough depressed examination becomes possible, and selected repeat ultrasound within 1–2 weeks when a tear is suspected. 1
For symptomatic PVD without a break or high-risk features, the inspected AAO follow-up table uses 4–6 weeks; some retinal or vitreous haemorrhage warrants earlier review, including 1–2 weeks or weekly according to the finding. The original universal 3–4 week rule must not delay high-risk eyes. Advise every patient to return promptly for new or worsening symptoms rather than waiting for the booked visit. 1
03Distinguish tractional breaks from low-risk peripheral changes
A horseshoe tear has a flap with continuing vitreous traction, allowing fluid to enter beneath the retina. Acute symptomatic tears usually need prompt retinopexy with laser or cryotherapy when the surrounding retina can be treated; an established detachment requires its own repair plan. Do not equate an isolated tear with an automatic indication for PPV. 1
Atrophic round holes and operculated holes differ from an acutely tractional flap tear. A free operculum suggests release of the focal attachment, but adjacent residual adhesion or another lesion can still matter. Most asymptomatic atrophic or operculated holes rarely require treatment; assess the whole eye and any fluid or progression. 1
A giant retinal tear (GRT) is commonly defined as extending at least 90 degrees, equivalent to three clock hours, with posterior vitreous separation. Preserve the original strict “>90 degrees” wording as a source discrepancy rather than treating exactly 90 degrees as reassuring. The retinal flap may fold back, described in the lecture as a Taco-configuration or Taco-Fold. 1 8
GRT repair may require release of edge traction, controlled unfolding with heavy liquid and retinopexy. The extent of laser belongs to the operative plan; the original mandatory 360 degree rule has not been established here for every affected eye. Studies of prophylactic 360 degree treatment in the attached fellow eye answer a different question and must not be used as proof of a therapeutic rule in the detached eye. 1 8
Retinal dialysis is a circumferential disinsertion at the ora serrata, often associated with trauma. A buckle or local explant (Plombe) can support the break while avoiding entry into the vitreous in a suitable young phakic eye; lens status, extent, traction and other findings can change that choice. Acute symptomatic dialysis still needs prompt specialist treatment assessment. 1 2
Lattice degeneration combines peripheral thinning, vitreous liquefaction and focal adhesion. It can contain atrophic holes or develop a tractional tear during PVD. High myopia or a fellow-eye detachment affects risk, but neither is by itself proof that all asymptomatic lattice requires laser. The AAO notes limited or absent randomised evidence for many prophylactic situations and no consensus in some fellow-eye cases. 1 4
Vitreoretinal tufts and meridional folds are focal interface abnormalities that deserve assessment for traction and associated breaks. Paving-stone or cobblestone degeneration instead describes peripheral chorioretinal atrophy: outer retina, retinal pigment epithelium (RPE) and choriocapillaris are affected, with remaining retinal layers adherent to Bruch’s membrane. That is more precise than the original fusion-to-RPE shortcut. 1 16
Typical paving-stone change, RPE hyperplasia and peripheral cystoid degeneration are not the same lesion as a tractional tear and generally do not justify prophylactic treatment on their label alone. Do not turn this into a guarantee of zero tear risk elsewhere in the eye; document the morphology and search separately for coexisting pathology when symptoms require it. 16
04Choose the operation and explain the trade-offs
Scleral buckling, pars plana vitrectomy (PPV) and selected pneumatic retinopexy (PnR) are different ways to close breaks and control the forces sustaining detachment. Lens status, anatomy, PVR, view, positioning ability and local expertise matter. A preference should be explained through those findings rather than presented as personal taste or a universal hierarchy. 1 2 6
The SPR trial randomised 416 phakic and 265 pseudophakic patients with medium-complexity RRD in separate lens-status trials. At 1 year, visual improvement favoured buckling in phakic eyes, with mean change −0.71 versus −0.56 logMAR (P=.0005), while cataract progression was greater after PPV. These results do not mean that all phakic detachments should receive a buckle. 6
In SPR’s pseudophakic group, primary anatomical success was 53.4% (71/133) after buckle versus 72.0% (95/132) after PPV (P=.002), without a significant difference in visual change. Follow-up completion was 93% in the phakic and 89% in the pseudophakic trial. Older techniques and optional added buckling in the PPV arm limit simple extrapolation to every current operation. 6
PIVOT randomised 176 adults, 88 per group, at one specialist centre to PnR or PPV. Actual eligibility required a single break or group within one clock hour in detached retina above the 8/4 o’clock meridians; other breaks in attached retina were allowed. It excluded inferior breaks in detached retina, obscuring media, PVR grade B or worse, previous index-eye RD/PPV and inability to posture, among other criteria. 5
At 12 months, mean ETDRS visual acuity was 79.9±10.4 letters after PnR versus 75.0±15.2 after PPV, a 4.9 letter difference (P=.024). Primary anatomical success favoured PPV: 80.8% (63/78) with PnR versus 93.2% (68/73) with PPV (P=.045); secondary success was 98.7% versus 98.6%. Better vision and more single-operation failures can coexist, so discuss both with a suitable patient. 5
Phakic cataract surgery occurred in 16% after PnR versus 65% after PPV by 1 year. PnR required somewhat more visits; visual-function questionnaire advantages at 3/6 months were not maintained at 1 year, and vertical rather than horizontal distortion favoured PnR. These secondary outcomes and multiple comparisons should not be turned into a promise of individual visual benefit. 5
PIVOT used stratified block randomisation, but missing 1 year vision was excluded despite its intention-to-treat label: clinical follow-up was 77/88 versus 73/88, and some outcomes use other denominators. Break imbalance, more rapid PnR delivery, different gases and cataract treatment can influence interpretation; the inspected main text does not clearly establish masked outcome assessment. Trial expertise, selection and missing data limit a universal first-line recommendation. 5
05Keep operative principles separate from a fixed recipe
The pars plana provides access for PPV; the original 23G/25G systems are retained as examples rather than a claim that one gauge or entry is safest in every eye. Identify breaks, assess traction and use controlled visualisation when inducing a PVD or shaving the vitreous base. These steps also carry risks and require surgical training. 1 2 5
Heavy perfluorocarbon liquid (PFCL) can help stabilise or unfold mobile retina during selected complex repairs. It is a surgical adjunct rather than a replacement for identifying breaks, relieving relevant traction and securing retinopexy. Follow the appropriate product instructions and avoid treating different heavy liquids as interchangeable. 5
Retinal autografting for refractory macular holes is a separate salvage topic retained from the original broad lecture. Published evidence is limited, and neither a named Finesse-Loop nor PFCL defines a universally required graft protocol. It should not be taught as a routine step in ordinary RRD repair. 13 14
The current FINESSE Flex Loop product information describes creating a membrane edge to begin peeling with forceps, with warnings against retinal scraping and using the device to remove the internal limiting membrane (ILM). That description does not establish the original proposed graft-guidance technique; use a specifically supported technique and actual device instructions rather than inferring an indication from the product name. 13
Tamponade supports the repair while retinopexy matures. Gas choice, mixture, fill, break location and positioning are individual decisions; C3F8 commonly lasts approximately 6–8 weeks in the inspected AAO macular-surgery discussion, but duration varies. Silicone oil lasts longer and usually entails a separate removal decision; PVR risk alone does not select one universal tamponade. 5 14
While intraocular gas remains, avoid air travel and high-altitude ascent until the treating team confirms it is safe, and tell any anaesthetist or emergency clinician that gas is present. Nitrous oxide can expand the bubble and dangerously raise pressure; this is not a prohibition of every form of anaesthesia. Provide a written alert and a clear postoperative plan. 14
06Recognise the mechanism before treating a complication
An unexpectedly elevated choroid during PPV requires immediate assessment of infusion, pressure and cannula position. Causes include hypotony, obstruction, leakage or misdirected infusion; do not assume that every choroidal detachment has one mechanism. 11 12
Stop inappropriate infusion, particularly misdirected air, and establish a securely verified intraocular route with situation-specific expert management. Suprachoroidal air can have serious systemic consequences. The original automatic nasal relocation is not established as a universal remedy; a small technical series describing repositioning is not a comparison of cannula sites. 11 12
PVR involves cellular proliferation, migration and contractile membranes that can shorten or re-detach the retina. RPE and glial cells and the wound/inflammatory response are relevant; it is too simple to blame laser alone or to claim that understanding the mechanism prevents every complication. 1 5
Complex PVR may require membrane dissection or peeling, further traction relief and an individual tamponade strategy. Anti-inflammatory treatment has its own indications, but it is not established here as a universal means of preventing PVR. PIVOT excluded PVR grade B or worse and cannot validate the original recipe for complex PVR surgery. 1 5
Exudative or serous detachment can show shifting subretinal fluid with posture, but that clue does not establish its cause. Inflammatory Vogt–Koyanagi–Harada disease (VKH), uveal-effusion syndromes and other causes require different work-up and treatment; corticosteroids are not a blanket remedy for every serous detachment. 9 10 15
Selected inflammatory disease may require corticosteroid and immunomodulatory care, while selected uveal-effusion cases have been treated with scleral decompression or drainage. A systematic review of 28 UES surgical articles found generally favourable anatomical reports but limited controlled evidence and incomplete harm reporting. These selected reports support cause-specific specialist decisions; they do not establish one preferred treatment for every exudative detachment. 9 10 15
07Act promptly and distinguish acute review from long-term care
A timing meta-analysis included 20 observational studies with 1929 patients. Macula-off repair 0–3 days after symptom onset was associated with better final acuity than 4–7 days: mean difference −0.06 logMAR (95% CI −0.09 to −0.03). For macula-on repair 0–24 hours from presentation versus later, the difference was −0.02 (−0.03 to −0.01). Neither comparison showed a significant difference in change from baseline. 7
Evidence quality was moderate for the macula-off and low for the macula-on comparison, with possible confounding by baseline acuity and imprecise symptom timing. These are modest average associations, not randomised proof of a safe deadline. PIVOT’s 24/72 hour trial rules do not establish a general permission to delay care. 7
After tear treatment or RD surgery, document what was treated, the remaining retina, pressure, tamponade, positioning and the next examination. The original operation-specific follow-up is individual: postoperative and tear-surveillance visits must not be replaced by the fixed PVD-without-tear interval. 1 2 14
Retinopexy does not prevent every new tear elsewhere, and new symptoms need prompt reassessment even after an apparently successful repair. Give the patient written warnings, a contact route and gas precautions where relevant; anatomical attachment, acuity, distortion and practical daily vision are separate outcomes to review. 1 14
08Connect the findings to the next step
Present the problem in a practical sequence: symptoms and visual function, vitreous/PVD and media clarity, peripheral break pattern and fluid, foveal involvement and PVR, then urgency and the selected repair or observation plan. Preserve uncertainty rather than forcing a single operation from one isolated finding. 1 2
The summary below retains all eight original comparison rows while separating a tear from an established detachment and a tractional problem from a benign lesion or an exudative cause. It is a review aid, not a substitute for examination, a trained operating surgeon or an individual postoperative plan. 1 5 6
| Finding / lesion | Risk context | Mechanism | Next step |
|---|---|---|---|
| Horseshoe tear | High when acute, symptomatic and tractional | Persistent traction at the flap | Complete peripheral examination; prompt laser/cryotherapy where appropriate, or RD repair if already detached. |
| Haemorrhagic PVD | Higher tear risk; view may be limited | Traction can tear a vessel and conceal breaks | B-scan with obscured view plus close follow-up; a negative scan does not exclude every tear. |
| Giant retinal tear, commonly ≥90 degrees | Complex tear/detachment | Mobile folded flap, sometimes Taco-Fold | Specialist repair with traction relief, selected PFCL, retinopexy and individual gas/oil; no unverified universal 360 degree rule. |
| Retinal dialysis | Assess symptoms, trauma and extent | Disinsertion at the ora serrata | Prompt treatment assessment; buckle/Plombe can suit selected young phakic eyes, other findings may favour another approach. |
| Paving-stone change | Usually low risk from this lesion itself | Chorioretinal atrophy with adhesion to Bruch’s membrane | No automatic lesion-directed treatment; investigate coexisting causes when new symptoms occur. |
| Exudative detachment | Cause-specific | Serous fluid; may shift with posture | Establish cause; selected medical or surgical care, rather than a universal operation prohibition or steroid rule. |
| PVR | Greater complexity and redetachment risk | Cell migration/proliferation and contracting membranes | Specialist traction/membrane management and individual tamponade; no proven universal anti-inflammatory prevention recipe here. |
| Symptoms without a detected tear | Depends on risk and examination quality | Evolving PVD or an obscured/missed/new break | Risk-based review; AAO 4–6 weeks without high-risk features, earlier with haemorrhage or new symptoms, not a universal 3–4 week wait. |
Which findings particularly influence the operation plan?
Describe the location and number of breaks, detachment extent and foveal or macular status, lens status, and presence and extent of PVR. Add media clarity, prior procedures, symptoms/timing, positioning ability and the individual patient’s needs; the original request for four findings should not hide relevant additional factors.
What is the key additional examination when the fundus cannot be adequately seen?
B-scan ultrasonography helps detect or map a detachment and assess other causes of obscuration. Its sensitivity for small tears is imperfect; combine it with close specialist review, repeat imaging when indicated and a complete peripheral retinal examination as soon as feasible. A negative first scan is not blanket reassurance.
References and access status
- 1AAO PVD, retinal breaks and lattice PPP2024/published 2025
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Actual downloaded PDF, selected text P172–175 and P177–182 including Tables 1–3 read. Full methods/appendices and actual table images not completely inspected. The original 3–4 week universal rule is retained archivally; current follow-up depends on risk, haemorrhage and symptoms.
- 2DOG/BVA22b rhegmatogenous retinal detachment, 2011
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. All three pages of actual extracted PDF text read, not a current comprehensive guideline. Refers to 22a for diagnostics, not separately read.
- 3AWMF045-033 RRD registration, 3 June 2026
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Official announcement read: Anmeldung, not a completed new clinical treatment guideline. No 2026 recommendations inferred.
- 4Original German S1 risk/prophylaxis 2022; PMID 36520163
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Original link preserved; indexed bibliographic record/title read, no abstract supplied. Springer download was HTML, not a PDF; full source unread. Original lattice 6–10% and C3F8 14% preparation claims remain source questions, not verified instructions.
- 5PIVOT randomised trial; PMID 30468761
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract and 9 page primary preproof text read, including methods/Tables 1–3/limitations; actual Figures 1/2 and Table 2/Figure 3 visually inspected. Supplement, protocol, SAP and registry unread. Actual Table 2 shows dexamethasone 400 µg/0.1 ml where extraction falsely read 400 mg; no dose adopted or source erratum inferred.
- 6SPR randomised trial, 2007; PMID 18054633
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; main report/protocol/supplements unread. Separate phakic/pseudophakic populations, historical techniques and optional added buckle limit generalisation.
- 7Timing meta-analysis, 2022; PMID 35932819
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; full study tables/bias assessment/supplements unread. Twenty observational studies, different symptom/presentation clocks and baseline-vision confounding; not randomised proof of a safe delay.
- 8Cochrane fellow-eye GRT prophylaxis, 2009; PMID 19370659
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; search to 15 December 2008, no eligible studies. Later updated/2025 reviews located but not fully appraised. Defines 90 degrees or more versus original >90 wording; attached-fellow-eye prophylaxis is distinct from laser in an affected-eye repair.
- 9UES surgical systematic review, 2025; PMID 40663118
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; 28 articles, full bias tables/main report unread. Selected causes have surgical options, with small-study and harm-reporting limits; not universal proof of benefit.
- 10UES retrospective surgical cohort, 2022; PMID 35755052
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; 106 eyes/66 patients, 2001–2021. Full report/tables unread; no comparator, clustering and selection. Abstract 98.1%/96.2% reattachment figures need denominator/time clarification and are not adopted as a general prognosis.
- 11Intraoperative choroidals/PAVE, 2024; PMID 39620693
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed video-article abstract read; main report/video not read/watched. Supports immediate stopping of misdirected air; its 40 mmHg mechanism is not a safe universal pressure threshold or proof of a mandatory nasal site.
- 12Infusion cannula localisation, 2014; PMID 25011023
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; 17 eyes/17 patients, technical series. Full report/video unread; repositioning described without establishing one universal cannula site or a validated diagnostic test.
- 13Alcon FINESSE Flex Loop product information
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Selected actual manufacturer indications/design/warnings read; full DFU/historical revision and videos unread. Original Finesse-Loop guidance under mandatory PFCL remains a technique/source question, not a verified universal graft recipe.
- 14AAO idiopathic macular-hole PPP2024/published 2025
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Selected actual gas/graft text P252 and precautions P255 reread from the parent 015 download. Not a full new 020 PPP appraisal. Approximate C3F8 6–8 week duration and travel/nitrous-oxide safety do not verify the original 14% product preparation. Full gas/device IFUs pending.
- 15VKH initial treatment cohort, 2023; PMID 37141529
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Complete indexed abstract read; 50 patients, retrospective two-centre cohort, full report unread. Corticosteroid/selected immunosuppressive context; the 26 day association is not a safe waiting deadline or causal trial. Separate 2024 review PMID 38657222 located as title/metadata only.
- 16AAO-hosted peripheral-lesion teaching slides, r36
Historical source appraisal from review 020 (5 November 2026); no new full-source access claimed here. Actual 230 slide PDF downloaded; selected classification/morphology text and actual slides 40/49 inspected. Remaining deck not completely read and date/version not verified. Slide 49 supports adhesion to Bruch’s membrane. Hidden animation text in extraction was distinguished from visible slide content; this is a teaching source, not a current comparative guideline.
- 17Own immutable original export
Own lecture and source wrapper read 15 November 2026; recording and attribution unverified.
Original lecture link
For patients
A retinal tear can let fluid pass under the light-sensitive layer at the back of the eye and detach it. Without timely assessment and treatment, sight may be permanently damaged even if the centre still seems to see well.
The team dilates the pupil to examine the retina; ultrasound may be needed when the view is blocked. Some tears can be sealed with laser or freezing, whereas a detachment usually needs a repair procedure. The method depends on the exact findings and your circumstances.
Keep every follow-up appointment and the instructions about drops and positioning. If a gas bubble was used, follow the written travel restrictions and tell other treating clinicians and anaesthetists about it; nitrous oxide must be avoided while intraocular gas remains. Ask the team when the bubble is gone and travel is safe.
New flashes, a sudden shower of black dots, a shadow or curtain, or new visual loss: seek an eye examination the same day. Take new symptoms especially seriously after an eye operation or injury. After surgery, worsening vision or severe pain also needs urgent contact; do not wait for a routine appointment. This information does not replace an individual examination or treatment plan.